Initial phase 1 trial results demonstrate that oral Muvalaplin effectively lowers lipoprotein (a) without any significant negative effects.

Published Date: 08 Sep 2023

Australia: Daily administration of the Lp(a) formation-selective small molecule inhibitor Muvalaplin for a period of 14 days reduced Lipoprotein(a) levels.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Scientists Employ Technology to Identify Plagiarism and Forgeries in Published Studies.

2.

GuCS: Genitourinary Cancers Symposium

3.

Obesity-associated cancers tripled nationwide over past two decades

4.

A new mechanism of radioresistance formation demonstrated in lung adenocarcinoma

5.

EGFR Inhibitors for Lung Cancer Tied to Increased Keratitis Risk.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot